Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Concert Pharmaceuticals

Nasdaq:CNCE
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CNCE
Nasdaq
$275M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The last earnings update was 30 days ago. More info.


Add to Portfolio Compare Print
  • Concert Pharmaceuticals has significant price volatility in the past 3 months.
CNCE Share Price and Events
7 Day Returns
14.3%
NasdaqGM:CNCE
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-22.5%
NasdaqGM:CNCE
0%
US Biotechs
-11.5%
US Market
CNCE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Concert Pharmaceuticals (CNCE) 14.3% -8.2% 8.5% -22.5% -45.2% -39.9%
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • CNCE underperformed the Biotechs industry which returned 0% over the past year.
  • CNCE underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
CNCE
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Concert Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Concert Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Concert Pharmaceuticals.

NasdaqGM:CNCE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:CNCE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (5.91%))
1.173
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.17
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.173 * 5.44%)
8.12%

Discounted Cash Flow Calculation for NasdaqGM:CNCE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Concert Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:CNCE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.12%)
2020 -85.31 Analyst x1 -78.90
2021 -85.42 Analyst x2 -73.07
2022 -81.52 Analyst x2 -64.49
2023 -43.34 Analyst x1 -31.71
2024 47.34 Analyst x1 32.04
2025 70.05 Est @ 47.97% 43.84
2026 93.93 Est @ 34.1% 54.37
2027 116.84 Est @ 24.39% 62.55
2028 137.40 Est @ 17.6% 68.03
2029 155.04 Est @ 12.84% 71.00
Present value of next 10 years cash flows $83.00
NasdaqGM:CNCE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $155.04 × (1 + 1.74%) ÷ (8.12% – 1.74%)
$2,471.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,471.20 ÷ (1 + 8.12%)10
$1,131.68
NasdaqGM:CNCE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $83.00 + $1,131.68
$1,214.68
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,214.68 / 29.44
$41.26
NasdaqGM:CNCE Discount to Share Price
Calculation Result
Value per share (USD) From above. $41.26
Current discount Discount to share price of $9.35
= -1 x ($9.35 - $41.26) / $41.26
77.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Concert Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $9.35 vs Future cash flow value of $41.26
Current Discount Checks
For Concert Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Concert Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Concert Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Concert Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Concert Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CNCE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.29
NasdaqGM:CNCE Share Price ** NasdaqGM (2020-03-27) in USD $9.35
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Concert Pharmaceuticals.

NasdaqGM:CNCE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CNCE Share Price ÷ EPS (both in USD)

= 9.35 ÷ -3.29

-2.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Concert Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Concert Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Concert Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:CNCE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
40.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Concert Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Concert Pharmaceuticals's assets?
Raw Data
NasdaqGM:CNCE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.25
NasdaqGM:CNCE Share Price * NasdaqGM (2020-03-27) in USD $9.35
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:CNCE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CNCE Share Price ÷ Book Value per Share (both in USD)

= 9.35 ÷ 4.25

2.2x

* Primary Listing of Concert Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Concert Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Concert Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Concert Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Concert Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Concert Pharmaceuticals expected to grow at an attractive rate?
  • Concert Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Concert Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Concert Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CNCE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CNCE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 40.9%
NasdaqGM:CNCE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 58.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CNCE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CNCE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 226 127 4
2023-12-31 134 47 4
2022-12-31 66 -53 -73 5
2021-12-31 14 -45 -93 5
2020-12-31 0 -85 -96 5
2020-03-28
NasdaqGM:CNCE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -49 -78
2019-09-30 1 -49 -79
2019-06-30 1 -45 -79
2019-03-31 1 -37 -73
2018-12-31 11 -48 -56
2018-09-30 11 -39 -41
2018-06-30 11 106 104
2018-03-31 11 105 104
2017-12-31 0 104 95
2017-09-30 0 99 89
2017-06-30 0 -45 -50
2017-03-31 0 -44 -50

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Concert Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Concert Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CNCE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Concert Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CNCE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 4.67 9.86 -0.53 2.00
2023-12-31 1.93 5.60 -1.75 2.00
2022-12-31 -2.25 -1.54 -3.18 3.00
2021-12-31 -3.37 -1.51 -5.00 6.00
2020-12-31 -3.39 -2.84 -4.28 7.00
2020-03-28
NasdaqGM:CNCE Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.29
2019-09-30 -3.32
2019-06-30 -3.34
2019-03-31 -3.13
2018-12-31 -2.40
2018-09-30 -1.78
2018-06-30 4.50
2018-03-31 4.55
2017-12-31 4.20
2017-09-30 3.97
2017-06-30 -2.22
2017-03-31 -2.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Concert Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Concert Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Concert Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Concert Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Concert Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Concert Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Concert Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Concert Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Concert Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Concert Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CNCE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.08 -78.17 20.28
2019-09-30 1.08 -78.53 20.81
2019-06-30 1.08 -78.73 22.38
2019-03-31 1.03 -73.39 22.92
2018-12-31 10.51 -56.02 22.94
2018-09-30 10.50 -41.25 22.65
2018-06-30 10.51 103.77 21.20
2018-03-31 10.52 104.07 21.40
2017-12-31 0.06 95.20 21.02
2017-09-30 0.07 89.23 19.35
2017-06-30 0.08 -49.76 17.91
2017-03-31 0.14 -50.17 16.03
2016-12-31 0.17 -50.72 14.36
2016-09-30 10.46 -37.99 14.10
2016-06-30 12.14 -35.19 13.93
2016-03-31 15.32 19.30 13.40
2015-12-31 16.57 24.17 13.06
2015-09-30 7.58 14.56 10.64
2015-06-30 10.29 15.29 12.98
2015-03-31 8.27 -33.75 12.40
2014-12-31 8.58 -31.75 11.70
2014-09-30 8.68 -28.84 10.45
2014-06-30 4.94 -28.24 7.69
2014-03-31 21.15 -13.46 7.94
2013-12-31 25.41 -6.45 8.03
2013-09-30 24.22 -8.29 10.75
2013-06-30 23.80 -10.02 10.44
2013-03-31 12.54 -18.82 10.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Concert Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Concert Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Concert Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Concert Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Concert Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Concert Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Concert Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Concert Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Concert Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Concert Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Concert Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Concert Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGM:CNCE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 101.46 0.00 111.81
2019-09-30 119.26 0.00 126.98
2019-06-30 133.70 0.00 141.74
2019-03-31 149.80 0.00 159.03
2018-12-31 167.74 0.00 160.84
2018-09-30 185.75 0.00 177.61
2018-06-30 200.28 0.00 190.17
2018-03-31 210.40 0.00 200.16
2017-12-31 196.43 0.00 203.17
2017-09-30 195.86 0.00 207.11
2017-06-30 64.38 29.19 103.42
2017-03-31 75.02 0.00 83.93
2016-12-31 85.59 0.00 96.19
2016-09-30 96.14 0.00 107.99
2016-06-30 106.18 0.00 118.42
2016-03-31 118.26 0.00 127.72
2015-12-31 130.64 0.00 142.19
2015-09-30 128.87 0.78 141.98
2015-06-30 135.74 2.93 151.70
2015-03-31 93.49 5.04 113.07
2014-12-31 54.83 7.10 79.23
2014-09-30 63.00 9.12 89.92
2014-06-30 69.70 11.51 98.33
2014-03-31 77.20 13.52 108.03
2013-12-31 0.60 15.50 32.68
2013-09-30 6.33 17.44 41.32
2013-06-30 13.59 19.33 52.65
2013-03-31 5.62 20.64 27.56
  • Concert Pharmaceuticals has no debt.
  • Concert Pharmaceuticals has no debt compared to 5 years ago when it was 12.8%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Concert Pharmaceuticals has sufficient cash runway for 2.3 years based on current free cash flow.
  • Concert Pharmaceuticals has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 2.5% each year.
X
Financial health checks
We assess Concert Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Concert Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Concert Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Concert Pharmaceuticals dividends.
If you bought $2,000 of Concert Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Concert Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Concert Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CNCE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CNCE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Concert Pharmaceuticals has not reported any payouts.
  • Unable to verify if Concert Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Concert Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Concert Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Concert Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Concert Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Concert Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Concert Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Roger Tung
COMPENSATION $4,607,848
AGE 59
TENURE AS CEO 13.9 years
CEO Bio

Dr. Roger D. Tung, Ph.D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and major pharmaceutical companies, including Vertex Pharmaceuticals from 1989 to 2005, where he was a Founding Scientist. He also served as a Vice President of Drug Discovery for San Diego site of Vertex Pharmaceuticals from February 2002 to January 2005. He co-invented and headed discovery of Vertex's two commercial HIV protease inhibitor products, Lexiva® and Agenerase®, and led development of Agenerase® in collaboration with Glaxo through FDA and EMEA approval. He has 30 year career in the global pharmaceutical and biotechnology industries in scientific and scientific management positions at the Squibb Institute for Medical Research, Merck Research Laboratories, Concert and Vertex Pharmaceuticals. He discovered both of the marketed products of Vertex Pharmaceuticals Incorporated. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider and The Squibb Institute for Medicinal Chemistry. He is Co-Founder, President and CEO of Concert Pharmaceuticals (NASDAQ: CNCE) and BOD, Flex Pharma (NASDAQ: FLKS) He has been a Director of Concert Pharmaceuticals, Inc. since April 2006. He had been a Director of Flex Pharma, Inc. since October 31, 2017 until July 19, 2019 and served as its Member of Scientific Advisory Board until October 31, 2017. He served as a Member of Scientific Advisory Board at Verastem, Inc., and Syros Pharmaceuticals, Inc. He serves as a Member of Scientific and Clinical Advisory Board at Medivation, Inc. (formerly, Orion Acquisition Corp. II.). He has published widely and been granted 47 U.S. patents. Dr. Tung received a BA in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.

CEO Compensation
  • Roger's compensation has increased whilst company is loss making.
  • Roger's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Concert Pharmaceuticals management team in years:

3.9
Average Tenure
61
Average Age
  • The tenure for the Concert Pharmaceuticals management team is about average.
Management Team

Rich Aldrich

TITLE
Co-Founder & Chairman of the Board
COMPENSATION
$206K
AGE
65

Roger Tung

TITLE
Co-Founder
COMPENSATION
$5M
AGE
59
TENURE
13.9 yrs

Marc Becker

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
47
TENURE
2.2 yrs

Nancy Stuart

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
61
TENURE
12.4 yrs

Justine Koenigsberg

TITLE
Senior Vice President of Corporate Communications and Investor Relations

Jeff Munsie

TITLE
Chief Legal Officer & Corporate Secretary
AGE
42
TENURE
0.5 yrs

Jim Cassella

TITLE
Chief Development Officer
COMPENSATION
$2M
AGE
64
TENURE
5.1 yrs

Ian Silverman

TITLE
Senior Legal Advisor
COMPENSATION
$540K
AGE
66
TENURE
2.8 yrs
Board of Directors Tenure

Average tenure and age of the Concert Pharmaceuticals board of directors in years:

12.8
Average Tenure
62.5
Average Age
  • The average tenure for the Concert Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Roger Tung

TITLE
Co-Founder
COMPENSATION
$5M
AGE
59
TENURE
13.9 yrs

Ron Barrett

TITLE
Independent Director
COMPENSATION
$185K
AGE
63
TENURE
12.3 yrs

Rich Aldrich

TITLE
Co-Founder & Chairman of the Board
COMPENSATION
$206K
AGE
65
TENURE
13.8 yrs

Thomas Auchincloss

TITLE
Independent Director
COMPENSATION
$189K
AGE
58
TENURE
5.3 yrs

Wilf Jaeger

TITLE
Independent Director
COMPENSATION
$181K
AGE
64
TENURE
13.8 yrs

Peter Hutt

TITLE
Independent Director
COMPENSATION
$181K
AGE
84
TENURE
13.3 yrs

Christi van Heek

TITLE
Independent Director
COMPENSATION
$181K
AGE
62
TENURE
3.9 yrs

Jesper Høiland

TITLE
Director
AGE
59
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Concert Pharmaceuticals individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. Mar 20 Buy Thomas Auchincloss Individual 12. Mar 20 12. Mar 20 1,500 $8.52 $12,773
04. Feb 20 Buy Thomas Auchincloss Individual 03. Feb 20 03. Feb 20 1,000 $10.91 $10,910
10. Oct 19 Buy Christine van Heek Individual 02. Aug 19 08. Oct 19 10,000 $10.84 $83,707
12. Jun 19 Sell BVF Partners LP Company 10. Jun 19 10. Jun 19 -386,289 $10.70 $-4,134,799
X
Management checks
We assess Concert Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Concert Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Shareholder Appears On The Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) Shareholder Register?

View our latest analysis for Concert Pharmaceuticals NasdaqGM:CNCE Ownership Summary, August 27th 2019 What Does The Institutional Ownership Tell Us About Concert Pharmaceuticals? … We can see that Concert Pharmaceuticals does have institutional investors; and they hold 56% of the stock. … Insider Ownership Of Concert Pharmaceuticals The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … Check out our latest analysis for Concert Pharmaceuticals How Does Roger Tung's Compensation Compare With Similar Sized Companies? … If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Concert Pharmaceuticals.

Simply Wall St -

How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' See our latest analysis for Concert Pharmaceuticals Concert Pharmaceuticals Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Co-Founder & Chairman of the Board Richard Aldrich for US$591k worth of shares, at about US$12.00 per share. … In the last twelve months Concert Pharmaceuticals insiders were buying shares, but not selling. … Insider Ownership of Concert Pharmaceuticals I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders.

Simply Wall St -

Did You Manage To Avoid Concert Pharmaceuticals's (NASDAQ:CNCE) 49% Share Price Drop?

Check out our latest analysis for Concert Pharmaceuticals With just US$1,031,000 worth of revenue in twelve months, we don't think the market considers Concert Pharmaceuticals to have proven its business plan. … But since the share price has dropped 49% in the last year, it seems like the market might have been over-excited previously. … Concert Pharmaceuticals is not the only stock that insiders are buying.

Simply Wall St -

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): What Does Its Beta Value Mean For Your Portfolio?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Have Insiders Been Buying Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Shares?

Concert Pharmaceuticals Insider Transactions Over The Last Year. … Over the last year, we can see that insiders have bought 52.00k shares worth US$615k … In the last twelve months there was more buying than selling by Concert Pharmaceuticals insiders

Simply Wall St -

Does The Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Share Price Tend To Follow The Market?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Could The Concert Pharmaceuticals Inc (NASDAQ:CNCE) Ownership Structure Tell Us Something Useful?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Concert Pharmaceuticals is a smaller company with a market capitalization of US$312m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

How Did Concert Pharmaceuticals Inc's (NASDAQ:CNCE) 52.0% ROE Fare Against The Industry?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) outperformed the biotechnology industry on the basis of its ROE – producing a higher 52.0% relative to the peer average of 22.1% over the past 12 months. … If CNCE borrows debt to invest in its business, its profits will be higher. … But ROE does not capture any debt, so we only see high profits and low equity, which is great on the surface.

Simply Wall St -

How Does Investing In Concert Pharmaceuticals Inc (NASDAQ:CNCE) Impact Your Portfolio?

If you are looking to invest in Concert Pharmaceuticals Inc’s (NASDAQ:CNCE), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … The second risk is market-wide, which arises from investing in the stock market. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one.

Simply Wall St -

Company Info

Description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer’s disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Details
Name: Concert Pharmaceuticals, Inc.
CNCE
Exchange: NasdaqGM
Founded: 2006
$275,235,893
29,436,994
Website: http://www.concertpharma.com
Address: Concert Pharmaceuticals, Inc.
65 Hayden Avenue,
Suite 3000N,
Lexington,
Massachusetts, 02421,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CNCE Common Stock Nasdaq Global Market US USD 13. Feb 2014
DB 73C Common Stock Deutsche Boerse AG DE EUR 13. Feb 2014
BRSE 73C Common Stock Berne Stock Exchange CH CHF 13. Feb 2014
Number of employees
Current staff
Staff numbers
70
Concert Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:46
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/10
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.